Automakers face an increasingly difficult environment as President Donald Trump’s tariffs and the removal of EV tax credits reshape supply chains and production strategy. Like the broader US economy, auto sales have been resilient thus far, as tariffs and other government policies motivate consumers to buy now. Automakers and dealers are capitalizing on the moment with incentives like employee pricing, but the short-term surge is unlikely to last.

The news: Coca-Cola and PepsiCo are expanding their portfolios by leaning into better-for-you trends and ingredient transparency. Our take: Even with Coca-Cola and PepsiCo’s massive brand equity, they face the same fundamental challenge as all CPG brands: competing against private labels offering innovative flavors at lower prices, and better-for-you upstarts chip away at brand loyalty. While ingredients like cane sugar and prebiotics may not sway every shopper, they appeal to increasingly fragmented consumer preferences. Expect more targeted innovations as soda makers try to balance nostalgia with modern demands for wellness, transparency, and functional benefits.

The news: AstraZeneca plans to invest $50 billion in US drug manufacturing and R&D by 2030. The big takeaway: Pouring billions into US builds isn’t an option for most generic drugmakers that operate on thin margins. This could result in shortages since companies that make generics may have to choose between exiting the market once tariffs take effect and raising prices when possible. Other players in this space might find it most beneficial to wait it out and see if Trump changes course yet again on tariff policy.

The news: Rare disease drugmaker Sarepta Therapeutics is pausing sales of a muscular dystrophy drug, Elevidys, after initially refusing an FDA request to halt sales due to safety concerns. The takeaway: Elevydis’ path to FDA approval was unconventional, but deemed appropriate at the time for a devastating disease. The new deaths and now paused sales serve as caution for both the FDA and drugmakers to balance the emotional sway of unmet medical needs with complete and continued clinical research.

The news: Insurance premiums are set to rise by 15% next year for the people who buy through the Affordable Care Act, per a new KFF analysis. Our take: While the Trump administration is eliminating the ACA tax credits, states where the president won the election account for 88% of ACA enrollment growth since 2020, per KFF research in April. When premium increases roll out across the ACA marketplace, and spillover into higher costs for hospitals and healthcare services, we expect plenty of political finger-pointing over fault, but little agreement on ways to improve US healthcare and keep consumers out of medical debt.

The trend: Consumer perception of healthcare providers worsens when they find out the doctor uses AI, according to research recently published in JAMA Network. Our take: Healthcare is inherently emotional, and many consumers might be under the impression that their doctor is using AI as a shortcut. In reality, the opposite might be true. Physicians use AI to make them more efficient and free them up to spend extra time with patients. But language and details matter, and providers and marketers must ensure this is reflected in their messaging.